科济药业(02171.HK) 表示，董事会已批准一项股份购回计划，自2025年5月8日起的150个香港交易日内，将根据股份购回授权在公开市场上购回不超过已发行股份总数1%的公司股份，所用资金来自非IPO募集资金，其中包括业务发展收入、利息收入及其他补贴。
经股东于2024年5月21日举行的股东周年大会上批准，公司最多可购回于有关普通决议案获通过之日已发行股份总数的10%、即最多5,756.44万股。科济药业已于去5月及6月，购回总计413.55万股，总代价约2,411.61万元，并于同年7月注销全部购回股份。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.